BIIB’s much-touted anti-LINGO drug produces ambiguous results in phase-2 trial: http://www.fiercebiotech.com/story/biogen-idecs-remyelination-drug-raises-hopes-and-some-fears-phii/2015-01-08 (FierceBiotech) http://www.thestreet.com/story/13004247/1/biogens-nerve-repair-drug-yields-mixed-results-in-key-eye-trial.html (Feuerstein) http://finance.yahoo.com/news/biogen-idec-reports-positive-top-123000814.html (BIIB PR)